PathGroup SmartGenomics Cancer-Specific Testing

PathGroup has launched cancer-specific SmartGenomics testing targeting lung, colon, brain, thyroid, and melanoma/GIST. The company uses multiple technologies to provide a complete genomic picture of a patient's individual care. Each panel offers tailored genomic testing using guidelines recommendations from the National Comprehensive Cancer Network. Standard-of-care diagnostic features include expanded RAS testing in colorectal cancer; EGFR, ALK, ROS1, RET, and MET in lung cancer; and BRAF and KIT mutation testing in melanoma, PathGroup said.